IOPtima Ltd. of Ramat Gan, Israel, has completed the three-month follow-up period for its initial human clinical study using the OT134 device. The laser-based therapy enables eye surgeons to operate and reduce internal eye pressure without penetrating the ocular membrane. So far, the results suggest that the laser filtration system may be a viable alternative to current glaucoma therapies.